Literature DB >> 15199066

Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex.

David G Winkler1, Changpu Yu, James C Geoghegan, Ethan W Ojala, John E Skonier, Diana Shpektor, May K Sutherland, John A Latham.   

Abstract

Noggin and sclerostin are bone morphogenetic protein (BMP) antagonists that modulate mitogenic activity through sequestering BMPs. Little is known of the interactions among this class of proteins. We show that recombinant sclerostin and noggin bound to each other with high affinity (K(D) = 2.92 nm). This observation has been extended to naturally expressed noggin and sclerostin from the rat osteosarcoma cell line, ROS 17/2.8, supporting a role for the complex in natural systems. The noggin-sclerostin complex was competitive with BMP binding and mutually attenuated the activity of each BMP antagonist. Collectively, the data demonstrate a novel and exquisite paradigm for the regulation of BMP activity through direct neutralization of the BMP and activation by co-localized BMP antagonist expression. The pleiotrophic nature of noggin and sclerostin represents a novel mechanism for the fine-tuning of BMP activity in bone homeostasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15199066     DOI: 10.1074/jbc.M400521200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Soluble repulsive guidance molecule c/hemojuvelin is a broad spectrum bone morphogenetic protein (BMP) antagonist and inhibits both BMP2- and BMP6-mediated signaling and gene expression.

Authors:  Mahta Nili; Ujwal Shinde; Peter Rotwein
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

Review 2.  Osteocyte regulation of bone mineral: a little give and take.

Authors:  G J Atkins; D M Findlay
Journal:  Osteoporos Int       Date:  2012-08       Impact factor: 4.507

Review 3.  Bone morphogenetic proteins and their antagonists.

Authors:  Elisabetta Gazzerro; Ernesto Canalis
Journal:  Rev Endocr Metab Disord       Date:  2006-06       Impact factor: 6.514

4.  Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation.

Authors:  Vaclav Veverka; Alistair J Henry; Patrick M Slocombe; Andrew Ventom; Barbara Mulloy; Frederick W Muskett; Mariusz Muzylak; Kevin Greenslade; Adrian Moore; Li Zhang; Jianhua Gong; Xueming Qian; Chris Paszty; Richard J Taylor; Martyn K Robinson; Mark D Carr
Journal:  J Biol Chem       Date:  2009-02-10       Impact factor: 5.157

5.  Differential regulation of the bone morphogenic protein antagonist chordin in human normal and osteoarthritic chondrocytes.

Authors:  G Tardif; J-P Pelletier; D Hum; C Boileau; N Duval; J Martel-Pelletier
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

Review 6.  Current, new and future treatments of osteoporosis.

Authors:  Pooneh Salari Sharif; Mohammad Abdollahi; Bagher Larijani
Journal:  Rheumatol Int       Date:  2010-07-30       Impact factor: 2.631

7.  Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle.

Authors:  Andrei N Mardaryev; Mohammed I Ahmed; Nikola V Vlahov; Michael Y Fessing; Jason H Gill; Andrey A Sharov; Natalia V Botchkareva
Journal:  FASEB J       Date:  2010-06-03       Impact factor: 5.191

Review 8.  Agonists and Antagonists of TGF-β Family Ligands.

Authors:  Chenbei Chang
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

9.  Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.

Authors:  Linda Kim Pham; Mengmeng Liang; Helty A Adisetiyo; Chun-Peng Liao; Michael B Cohen; Stanley M Tahara; Baruch Frenkel; Noriyuki Kasahara; Pradip Roy-Burman
Journal:  Endocr Relat Cancer       Date:  2013-11-04       Impact factor: 5.678

Review 10.  The DAN family: modulators of TGF-β signaling and beyond.

Authors:  Kristof Nolan; Thomas B Thompson
Journal:  Protein Sci       Date:  2014-06-02       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.